Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

Core Insights - AbbVie has developed a significant oncology franchise, expanding from blood cancer drugs to include therapies for solid tumors, totaling five oncology products [1] - The oncology segment contributed over 11% to AbbVie's revenues in the first half of 2025, with a year-over-year growth of 5% [2] - Third-quarter 2025 oncology sales are estimated at $1.71 billion, reflecting nearly 2% growth year-over-year, despite declining sales of Imbruvica due to competition [3] AbbVie's Oncology Performance - AbbVie's oncology sales are projected to reach $1.71 billion in Q3 2025, with contributions from Venclexta, Epkinly, and Elahere, while Imbruvica continues to face challenges [7] - The recent approval of Emrelis for lung cancer is expected to provide modest revenue contributions in the upcoming quarter [3][7] Competitive Landscape - Major competitors in the oncology market include AstraZeneca, Merck, and Pfizer, with AstraZeneca's oncology sales accounting for nearly 43% of its total revenues, growing 11% in the first half of 2025 [5] - Merck's Keytruda, a PD-L1 inhibitor, represented over 48% of its total revenues in the first half of 2025, highlighting its significance in the oncology space [6] - Pfizer's oncology revenues grew 9% operationally in the first half of 2025, driven by several key drugs, now making up over 25% of its total revenues [6]